Access Menu

Log in via Social

Log in with LinkedIn


The Vein-Eye CARRY will solve the everyday painful problem of missed vein punctures. This is a revolutionary new hardware technology.

Verify Investor Status to make a reservation

Deal Type


Funding Goal


Current Reservations


Minimum Reservation


Maximum Reservation


Deal Stage

Bridge to Series B

Pre-money Valuation


Open Date


Closing Date


Deal Exemption Type


Elevator Pitch

We would like to offer you an opportunity to invest. We are looking for funds to build the Vein-Eye® CARRY inventory. We have distributors and end users anxious to purchase.

Company Overview

The Vein-Eye CARRY is a portable, lightweight, and revolutionary new medical device that solves the problem of painful missed vein punctures. It is able to be taken into the home, from room to room in a hospital, and positioned in an ambulance.

There are 30M – 40M vein punctures everyday worldwide.

Locating a vein to insert a needle can be difficult in any patient, but they are very difficult when the patient is very young, aged, obese or has very dark skin.

Care delays occur in approximately 25 percent of all patients regardless of care setting due to the inability to establish IV access.

Drawing blood or placing an IV is very difficult if the patient has diarrhea, is very young, is very old, or the veins have collapsed due to dehydration.

Drawing blood or placing an IV can be dangerous to both the patient and healthcare practitioner if the patient has COVID-19, Ebola, AIDS, SARS, Measles, Chicken Pox or Tuberculosis.

The failure rate of puncturing a vein is 10% to 40% when resuscitating a critically-ill patient, where time is of the essence and vein punctures are challenging.

One in three attempts result in failure in adults, and one in two attempts result in failure in pediatrics. That translates to 50% failure in pediatrics.

If intravenous therapy does not begin promptly, both patients and healthcare practitioners endure tremendous stress and discomfort with repeated missed attempts.

Key Customers & Partners

MedPro Associates Henry Schein HyGreen

Risks & Disclosures

The company, or the vein illumination technology, could be purchased by a larger medical equipment, or medical pharma, company. The per share price invested today will always be lower than the price of any buyout. The investor will always have a positive return of investment.